Episurf Medical AB (publ) (EPIS-B.ST)
SEK 0.14
(7.62%)
SEK 0.14
(7.62%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 3.7 Million SEK | 94.74% |
| 2022 | 1.9 Million SEK | 0.0% |
| 2021 | 1.9 Million SEK | -5.0% |
| 2020 | 2 Million SEK | 11.11% |
| 2019 | 1.8 Million SEK | 20.0% |
| 2018 | 1.5 Million SEK | -10.82% |
| 2017 | 1.68 Million SEK | 52.07% |
| 2016 | 1.1 Million SEK | -4.2% |
| 2015 | 1.15 Million SEK | -21.65% |
| 2014 | 1.47 Million SEK | 173.16% |
| 2013 | 539.48 Thousand SEK | 30.29% |
| 2012 | 414.04 Thousand SEK | 0.0% |
| 2011 | - SEK | 0.0% |
| 2010 | - SEK | 0.0% |
| 2009 | - SEK | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 3.2 Million SEK | -5.88% |
| 2024 Q3 | 3.4 Million SEK | 6.25% |
| 2024 Q1 | 3.4 Million SEK | -8.11% |
| 2023 Q4 | 3.7 Million SEK | 48.0% |
| 2023 Q3 | 2.5 Million SEK | -3.85% |
| 2023 Q2 | 2.6 Million SEK | 30.0% |
| 2023 FY | 3.7 Million SEK | 94.74% |
| 2023 Q1 | 2 Million SEK | 5.26% |
| 2022 FY | 1.9 Million SEK | 0.0% |
| 2022 Q4 | 1.9 Million SEK | 5.56% |
| 2022 Q3 | 1.8 Million SEK | -5.26% |
| 2022 Q2 | 1.9 Million SEK | 18.75% |
| 2022 Q1 | 1.6 Million SEK | -15.79% |
| 2021 Q1 | 1.8 Million SEK | -10.0% |
| 2021 FY | 1.9 Million SEK | -5.0% |
| 2021 Q3 | 2 Million SEK | 11.11% |
| 2021 Q4 | 1.9 Million SEK | -5.0% |
| 2021 Q2 | 1.8 Million SEK | 0.0% |
| 2020 Q3 | 1.7 Million SEK | -10.53% |
| 2020 Q4 | 2 Million SEK | 17.65% |
| 2020 FY | 2 Million SEK | 11.11% |
| 2020 Q2 | 1.9 Million SEK | 0.0% |
| 2020 Q1 | 1.9 Million SEK | 5.56% |
| 2019 Q1 | 1.5 Million SEK | 0.0% |
| 2019 Q2 | 1.4 Million SEK | -6.67% |
| 2019 Q3 | 1.7 Million SEK | 21.43% |
| 2019 Q4 | 1.8 Million SEK | 5.88% |
| 2019 FY | 1.8 Million SEK | 20.0% |
| 2018 Q2 | 1.9 Million SEK | 18.75% |
| 2018 FY | 1.5 Million SEK | -10.82% |
| 2018 Q4 | 1.5 Million SEK | -16.67% |
| 2018 Q3 | 1.8 Million SEK | -5.26% |
| 2018 Q1 | 1.6 Million SEK | -4.87% |
| 2017 Q3 | 1.44 Million SEK | 27.02% |
| 2017 FY | 1.68 Million SEK | 52.07% |
| 2017 Q4 | 1.68 Million SEK | 16.53% |
| 2017 Q2 | 1.13 Million SEK | -7.52% |
| 2017 Q1 | 1.22 Million SEK | 11.09% |
| 2016 Q3 | 1.07 Million SEK | -9.34% |
| 2016 Q4 | 1.1 Million SEK | 2.47% |
| 2016 FY | 1.1 Million SEK | -4.2% |
| 2016 Q1 | 1.21 Million SEK | 5.12% |
| 2016 Q2 | 1.19 Million SEK | -1.91% |
| 2015 Q4 | 1.15 Million SEK | -7.77% |
| 2015 Q1 | 1.49 Million SEK | 1.49% |
| 2015 FY | 1.15 Million SEK | -21.65% |
| 2015 Q3 | 1.25 Million SEK | -12.41% |
| 2015 Q2 | 1.42 Million SEK | -4.44% |
| 2014 Q1 | 792.53 Thousand SEK | 46.91% |
| 2014 FY | 1.47 Million SEK | 173.16% |
| 2014 Q4 | 1.47 Million SEK | 18.93% |
| 2014 Q3 | 1.23 Million SEK | 2.95% |
| 2014 Q2 | 1.2 Million SEK | 51.86% |
| 2013 Q2 | 571.64 Thousand SEK | 38.66% |
| 2013 Q1 | 412.26 Thousand SEK | -0.43% |
| 2013 Q3 | 610.36 Thousand SEK | 6.77% |
| 2013 Q4 | 539.48 Thousand SEK | -11.61% |
| 2013 FY | 539.48 Thousand SEK | 30.29% |
| 2012 Q2 | - SEK | 0.0% |
| 2012 Q1 | - SEK | 0.0% |
| 2012 FY | 414.04 Thousand SEK | 0.0% |
| 2012 Q4 | 414.04 Thousand SEK | 0.0% |
| 2012 Q3 | - SEK | 0.0% |
| 2011 Q3 | - SEK | 0.0% |
| 2011 Q2 | - SEK | 0.0% |
| 2011 Q1 | - SEK | 0.0% |
| 2011 FY | - SEK | 0.0% |
| 2011 Q4 | - SEK | 0.0% |
| 2010 FY | - SEK | 0.0% |
| 2010 Q4 | - SEK | 0.0% |
| 2009 FY | - SEK | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Acarix AB (publ) | 6.83 Million SEK | 45.899% |
| ADDvise Group AB (publ) | 121.2 Million SEK | 96.947% |
| ADDvise Group AB (publ) | 121.2 Million SEK | 96.947% |
| Arcoma AB | 28.02 Million SEK | 86.798% |
| Bactiguard Holding AB (publ) | 29.64 Million SEK | 87.519% |
| BICO Group AB (publ) | 493.1 Million SEK | 99.25% |
| Boule Diagnostics AB (publ) | 62.4 Million SEK | 94.071% |
| CellaVision AB (publ) | 126.03 Million SEK | 97.064% |
| Clinical Laserthermia Systems AB (publ) | 6.11 Million SEK | 39.493% |
| Chordate Medical Holding AB (publ) | 1.77 Million SEK | -108.931% |
| C-Rad AB (publ) | 64.09 Million SEK | 94.228% |
| Duearity AB (publ) | 4.15 Million SEK | 11.036% |
| Dignitana AB (publ) | 7.41 Million SEK | 50.088% |
| Getinge AB (publ) | 6.41 Billion SEK | 99.942% |
| Scandinavian Real Heart AB (Publ) | -1.68 Million SEK | 319.797% |
| Iconovo AB (publ) | -4.86 Million SEK | 176.1% |
| Integrum AB (publ) | 22.36 Million SEK | 83.454% |
| Luxbright AB (publ) | 8000.00 SEK | -46150.0% |
| Mentice AB (publ) | 14.1 Million SEK | 73.766% |
| OssDsign AB (publ) | 4.3 Million SEK | 14.033% |
| Paxman AB (publ) | 19.99 Million SEK | 81.499% |
| Promimic AB (publ) | 330 Thousand SEK | -1021.212% |
| Qlife Holding AB (publ) | 7.29 Million SEK | 49.259% |
| SciBase Holding AB (publ) | 11.91 Million SEK | 68.957% |
| ScandiDos AB (publ) | 22.69 Million SEK | 83.693% |
| Sectra AB (publ) | 36.59 Million SEK | 89.888% |
| Sedana Medical AB (publ) | 42.97 Million SEK | 91.39% |
| Senzime AB (publ) | 20.34 Million SEK | 81.809% |
| SpectraCure AB (publ) | 1.00 SEK | -369999900.0% |
| Stille AB | 66.55 Million SEK | 94.441% |
| Vitrolife AB (publ) | 413 Million SEK | 99.104% |
| Xvivo Perfusion AB (publ) | 141.6 Million SEK | 97.387% |